MK-3475/BCG in High Risk Superficial Bladder Cancer
Public ClinicalTrials.gov record NCT02324582. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Study of MK-3475 in Combination With BCG for Patients With High Risk Superficial Bladder Cancer
Study identification
- NCT ID
- NCT02324582
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Southern Illinois University
- Other
- Enrollment
- 18 participants
Conditions and interventions
Conditions
Interventions
- Intravenous MK-3475/ Intravesical BCG Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2015
- Primary completion
- Nov 17, 2021
- Completion
- Mar 26, 2023
- Last update posted
- Sep 2, 2024
2015 – 2023
United States locations
- U.S. sites
- 3
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Simmons Cancer Institute-SIU School of Medicine | Springfield | Illinois | 62702 | — |
| Southern Illinois University School of Medicine | Springfield | Illinois | 62702 | — |
| Henry Ford Health Systems | Detroit | Michigan | 48202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02324582, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 2, 2024 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02324582 live on ClinicalTrials.gov.